Completed × Graft vs Host Disease × Busulfan × Clear all
NCT00611351 2023-10-23

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

University of Nebraska

Phase 2 Completed
5 enrolled 10 charts
NCT00003270 2019-12-13

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Roswell Park Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00003414 2015-07-20

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 3 Completed
50 enrolled
NCT00014469 2013-03-07

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
NCT00003661 2011-03-07

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Roswell Park Cancer Institute

Phase 2 Completed
3 enrolled
NCT00054340 2010-05-14

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

Fred Hutchinson Cancer Center

Phase 1/2 Completed
NCT00346359 2010-05-14

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
40 enrolled